EVOK
Price
$2.54
Change
+$0.12 (+4.96%)
Updated
Apr 24, 04:56 PM (EDT)
Capitalization
5.17M
NBIX
Price
$105.75
Change
+$2.53 (+2.45%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
13.72B
11 days until earnings call
Ad is loading...

EVOK vs NBIX

Header iconEVOK vs NBIX Comparison
Open Charts EVOK vs NBIXBanner chart's image
Evoke Pharma
Price$2.54
Change+$0.12 (+4.96%)
Volume$100
Capitalization5.17M
Neurocrine Biosciences
Price$105.75
Change+$2.53 (+2.45%)
Volume$39.61K
Capitalization13.72B
EVOK vs NBIX Comparison Chart
Loading...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVOK vs. NBIX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVOK is a Buy and NBIX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (EVOK: $2.42 vs. NBIX: $103.22)
Brand notoriety: EVOK and NBIX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVOK: 54% vs. NBIX: 128%
Market capitalization -- EVOK: $5.17M vs. NBIX: $13.72B
EVOK [@Pharmaceuticals: Other] is valued at $5.17M. NBIX’s [@Pharmaceuticals: Other] market capitalization is $13.72B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVOK’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • EVOK’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, EVOK is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVOK’s TA Score shows that 5 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).

  • EVOK’s TA Score: 5 bullish, 3 bearish.
  • NBIX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both EVOK and NBIX are a good buy in the short-term.

Price Growth

EVOK (@Pharmaceuticals: Other) experienced а +12.56% price change this week, while NBIX (@Pharmaceuticals: Other) price change was +3.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.61%. For the same industry, the average monthly price growth was -4.57%, and the average quarterly price growth was -11.30%.

Reported Earning Dates

EVOK is expected to report earnings on Mar 13, 2025.

NBIX is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.61% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than EVOK($5.17M). NBIX YTD gains are higher at: -24.381 vs. EVOK (-45.249). NBIX has higher annual earnings (EBITDA): 358M vs. EVOK (-7.29M). NBIX has more cash in the bank: 1.03B vs. EVOK (4.74M). EVOK has less debt than NBIX: EVOK (5M) vs NBIX (428M). NBIX has higher revenues than EVOK: NBIX (1.89B) vs EVOK (5.18M).
EVOKNBIXEVOK / NBIX
Capitalization5.17M13.7B0%
EBITDA-7.29M358M-2%
Gain YTD-45.249-24.381186%
P/E RatioN/A57.20-
Revenue5.18M1.89B0%
Total Cash4.74M1.03B0%
Total Debt5M428M1%
FUNDAMENTALS RATINGS
EVOK vs NBIX: Fundamental Ratings
EVOK
NBIX
OUTLOOK RATING
1..100
116
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
9857
PRICE GROWTH RATING
1..100
9080
P/E GROWTH RATING
1..100
7190
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVOK's Valuation (41) in the Pharmaceuticals Other industry is in the same range as NBIX (70) in the Biotechnology industry. This means that EVOK’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as EVOK (100) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to EVOK’s over the last 12 months.

NBIX's SMR Rating (57) in the Biotechnology industry is somewhat better than the same rating for EVOK (98) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew somewhat faster than EVOK’s over the last 12 months.

NBIX's Price Growth Rating (80) in the Biotechnology industry is in the same range as EVOK (90) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to EVOK’s over the last 12 months.

EVOK's P/E Growth Rating (71) in the Pharmaceuticals Other industry is in the same range as NBIX (90) in the Biotechnology industry. This means that EVOK’s stock grew similarly to NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOKNBIX
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 21 days ago
90%
Bearish Trend 17 days ago
61%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
POWI47.160.92
+1.99%
Power Integrations
PHX3.940.06
+1.55%
PHX Minerals
XERS4.130.03
+0.73%
Xeris Biopharma Holdings
ALZN0.69N/A
N/A
Alzamend Neuro Inc.
INSM70.74-0.50
-0.70%
Insmed

EVOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-3.20%
RDHL - EVOK
33%
Loosely correlated
-2.60%
NBIX - EVOK
28%
Poorly correlated
+1.45%
EOLS - EVOK
26%
Poorly correlated
+7.36%
PRFX - EVOK
25%
Poorly correlated
+2.68%
EVO - EVOK
24%
Poorly correlated
+2.90%
More

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+1.45%
LFCR - NBIX
32%
Poorly correlated
+2.43%
EOLS - NBIX
30%
Poorly correlated
+7.36%
ACET - NBIX
25%
Poorly correlated
+5.90%
HROW - NBIX
24%
Poorly correlated
+3.97%
ALKS - NBIX
23%
Poorly correlated
+0.15%
More